Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd.
“We are very pleased and excited to work with A. Menarini Diagnostics to bring to market our advanced wearable insulin pump solution. The device provides up to 3.5 days of wear time to enable twice-a-week change routine and comes with a smartphone app that displays user’s pump data,” said Jesse J. Kim, CEO of EOFlow Co., Ltd., “The relationships that A. Menarini Diagnostics has established with patients and healthcare providers in the diabetes community, and their extensive distribution expertise will positively position us to deliver to key international markets.”
The innovative EOFlow Patch Pump was specifically chosen to integrate within A. Menarini Diagnostics’s connected diabetes care platform. According to the agreement, the two companies are forming a long-term partnership where A. Menarini Diagnostics will perform sales, marketing, training, and customer support for the EOFlow Patch Pump in EMEA and selected other countries.
“We are extremely proud to have signed such an important long term partnership allowing patients to add a powerful tool to better manage blood glucose levels and prevent diabetes complications. ” said Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics S.r.l.,”This agreement is part of our strategy of developing a portfolio of fully integrated innovative products for an enhanced management of diabetes and an improved quality of life for patients. ”
In addition, A. Menarini Diagnostics S.r.l. and EOFlow are discussing terms to commercialize additional innovative systems.
EOFlow is a wearable medical device company founded in 2011, with offices in Seoul, South Korea and San Jose, California, developing innovative drug delivery systems based on its proprietary pumping technology. The Company’s first product is EOPatch, a fully-functional, wearable, disposable insulin pump for people with diabetes. EOFlow is also developing a proprietary “closed loop” insulin delivery platform including a wearable ‘artificial pancreas’ product that integrates a continuous glucose sensor and an insulin pump into one wearable module, which recently achieved FDA’s Breakthrough Device Designation.
For more information please visit us at www.eoflow.com or follow us on Twitter: @EOPatch.
About A. Menarini Diagnostics S.r.l.
A.Menarini Diagnostics, is operating for more than 35 years in the In-Vitro Diagnostics industry - through its Affiliates and network of partners around the world. Structured around three main business units - Core Lab, Cell Pathology and Self Testing - it provides laboratories and patients with a full spectrum of solutions to better manage complex diseases.
A.Menarini Diagnostics belongs to the Menarini Pharmaceutical Group which was founded in 1886. Today it is present in 136 countries throughout the world, it counts 17,632 employees and has a 2018 turnover of € 3.6 billion.
For further information, please visit www.menarinidiagnostics.com